Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines against Group A
group A streptococcus
lipopeptide subunit vaccine
liposomes
nanoparticles
polyelectrolyte complexes
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
26 Apr 2020
26 Apr 2020
Historique:
received:
03
04
2020
revised:
20
04
2020
accepted:
23
04
2020
entrez:
3
5
2020
pubmed:
3
5
2020
medline:
3
5
2020
Statut:
epublish
Résumé
Peptide subunit vaccines hold great potential compared to traditional vaccines. However, peptides alone are poorly immunogenic. Therefore, it is of great importance that a vaccine delivery platform and/or adjuvant that enhances the immunogenicity of peptide antigens is developed. Here, we report the development of two different systems for the delivery of lipopeptide subunit vaccine (LCP-1) against group A streptococcus: polymer-coated liposomes and polyelectrolyte complexes (PECs). First, LCP-1-loaded and alginate/trimethyl chitosan (TMC)-coated liposomes (Lip-1) and LCP-1/alginate/TMC PECs (PEC-1) were examined for their ability to trigger required immune responses in outbred Swiss mice; PEC-1 induced stronger humoral immune responses than Lip-1. To further assess the adjuvanting effect of anionic polymers in PECs, a series of PECs (PEC-1 to PEC-5) were prepared by mixing LCP-1 with different anionic polymers, namely alginate, chondroitin sulfate, dextran, hyaluronic acid, and heparin, then coated with TMC. All produced PECs had similar particle sizes (around 200 nm) and surface charges (around + 30 mV). Notably, PEC-5, which contained heparin, induced higher antigen-specific systemic IgG and mucosal IgA titers than all other PECs. PEC systems, especially when containing heparin and TMC, could function as a promising platform for peptide-based subunit vaccine delivery for intranasal administration.
Identifiants
pubmed: 32357402
pii: nano10050823
doi: 10.3390/nano10050823
pmc: PMC7712447
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : APP1132975
Références
Immunol Cell Biol. 2009 Jul;87(5):391-9
pubmed: 19417770
J Control Release. 2019 Jun 10;303:130-150
pubmed: 31022431
Nat Rev Drug Discov. 2002 Feb;1(2):140-8
pubmed: 12120095
J Immunol. 1999 Jan 15;162(2):1064-70
pubmed: 9916734
Nanomedicine (Lond). 2016 Dec;11(24):3223-3235
pubmed: 27830630
Front Cell Infect Microbiol. 2013 Mar 25;3:13
pubmed: 23532930
Expert Opin Drug Deliv. 2016;13(2):167-70
pubmed: 26578092
Immunol Res. 2005;31(3):189-206
pubmed: 15888911
ACS Med Chem Lett. 2019 Jul 24;10(9):1253-1259
pubmed: 31531193
Biochem J. 2004 Aug 15;382(Pt 1):269-78
pubmed: 15147241
PLoS One. 2012;7(8):e40928
pubmed: 22936972
Curr Med Chem. 2020;27(17):2887-2901
pubmed: 30362416
Expert Opin Ther Pat. 2014 Apr;24(4):453-70
pubmed: 24456079
Expert Rev Vaccines. 2014 Nov;13(11):1361-76
pubmed: 25155636
Vaccines (Basel). 2019 Jul 01;7(3):
pubmed: 31266253
Evid Based Complement Alternat Med. 2016;2016:7659684
pubmed: 27493674
J Control Release. 2015 Jun 28;208:121-129
pubmed: 25869965
Nanomaterials (Basel). 2020 Jan 22;10(2):
pubmed: 31978968
Vaccine. 2013 Oct 1;31(42):4812-9
pubmed: 23933339
Chem Sci. 2016 Feb 1;7(2):842-854
pubmed: 28791117
Int Immunol. 2000 Nov;12(11):1511-9
pubmed: 11058570
PeerJ. 2019 Jan 14;6:e6185
pubmed: 30656066
J Infect Dis. 2020 Mar 2;221(6):934-942
pubmed: 31621864
Bioorg Med Chem. 2019 Jul 15;27(14):3082-3088
pubmed: 31176567
Sci Adv. 2020 Jan 29;6(5):eaax2285
pubmed: 32064333
Clin Dev Immunol. 2013;2013:387023
pubmed: 23533454
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Acta Biomater. 2016 Sep 1;41:161-8
pubmed: 27063491
Expert Rev Vaccines. 2009 Jul;8(7):937-53
pubmed: 19538118
Front Immunol. 2017 Mar 27;8:327
pubmed: 28396662
Eur J Med Chem. 2019 Oct 1;179:100-108
pubmed: 31247372
J Biol Chem. 2006 Jul 21;281(29):19872-80
pubmed: 16624819
Eur J Pharm Sci. 2001 Oct;14(3):201-7
pubmed: 11576824
Eur J Pharm Biopharm. 2015 Jun;93:242-53
pubmed: 25907005
Biochem Soc Trans. 2006 Jun;34(Pt 3):409-13
pubmed: 16709174
Vaccine. 2019 May 27;37(24):3167-3178
pubmed: 31047671
Acta Biomater. 2018 Oct 15;80:278-287
pubmed: 30266637
Vaccine. 2016 May 23;34(24):2692-9
pubmed: 27109567
Curr Top Med Chem. 2014;14(9):1194-208
pubmed: 24678703
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1650-62
pubmed: 18848591
Vaccine. 2009 Jan 29;27(5):660-5
pubmed: 19056446
Methods Mol Biol. 2011;751:297-308
pubmed: 21674338
Drug Discov Today. 2017 Nov;22(11):1697-1706
pubmed: 28683256
Nanomedicine (Lond). 2016 May;11(10):1223-36
pubmed: 27077314
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
Nat Rev Drug Discov. 2007 May;6(5):404-14
pubmed: 17473845
Nat Rev Drug Discov. 2010 Apr;9(4):293-307
pubmed: 20380038
Nanomedicine (Lond). 2014 Dec;9(17):2657-69
pubmed: 25529569
Annu Rev Chem Biomol Eng. 2019 Jun 7;10:337-359
pubmed: 31173518
Int J Pharm. 2017 Sep 15;530(1-2):128-138
pubmed: 28698066
Hum Vaccin Immunother. 2014;10(3):778-96
pubmed: 24300669
Vaccine. 2016 Jun 3;34(26):2953-2958
pubmed: 27032515
Carbohydr Polym. 2020 May 15;236:116041
pubmed: 32172855